AU Patent

AU2010233718B2 — Crystal forms of Saxagliptin

Assigned to Sandoz AG · Expires 2015-11-05 · 11y expired

What this patent protects

The present invention relates to novel polymorphic forms of Saxagliptin Hydrochloride. The present invention also relates to methods of making polymorphic forms of Saxagliptin Hydrochloride.

USPTO Abstract

The present invention relates to novel polymorphic forms of Saxagliptin Hydrochloride. The present invention also relates to methods of making polymorphic forms of Saxagliptin Hydrochloride.

Drugs covered by this patent

saxagliptin-hydrochloride (SAXAGLIPTIN HYDROCHLORIDE)

Patent Metadata

Patent number: AU2010233718B2
Jurisdiction: AU
Classification: —
Expires: 2015-11-05
Drug substance claim: No
Drug product claim: No
Assignee: Sandoz AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.